Camurus ABCAMRF -3.57%79 Days Payable is 204.12 as of Mar. 2026, which is 30% below its 10-year median of 291.12. GuruFocus rates CAMRF with a GF Score™ of 79/100 and a GF Value™ of $83.22 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 708 Biotechnology companies, Camurus AB ranks better than 60.45% on this metric.
Camurus AB's average Accounts Payable for the
three
months ended in Mar. 2026 was $8.9 Mil. Camurus AB's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $4.0 Mil.
Hence, Camurus AB's Days Payable for the
three
months ended in Mar. 2026 was 204.12.
The historical rank and industry rank for Camurus AB's Days Payable or its related term are showing as below:
CAMRF'
s Days Payable Range Over the Past 10 Years
Min: 157.31 Med: 291.12 Max: 4393.73
Current: 177.77
During the past 13 years, Camurus AB's highest Days Payable was 4393.73. The lowest was 157.31. And the median was 291.12.
CAMRF's Days Payable is ranked better than 60.45% of 708
companies
in the Biotechnology industry
Industry Median: 113.56
vs CAMRF: 177.77
Camurus AB's Days Payable
increased
from Mar. 2025 (202.39) to Mar. 2026 (204.12).
It may suggest that Camurus ABdelayed paying its suppliers.
Camurus AB Days Payable Related Terms
Camurus AB Days Payable Historical Data
* Premium members only.
The historical data trend for Camurus AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Camurus AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Camurus AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Camurus AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a Days Payable of 204.12 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Camurus AB and its competitors. This is 30% below median its historical median of 291.12. Over the past decade, Camurus AB's Days Payable has ranged from 157.31 to 4,393.73. According to the industry distribution chart, Camurus AB ranks #280 out of 708 companies in the Biotechnology industry, placing it in the top 39.5%.
Is Camurus AB's Days Payable too high?
Camurus AB's current Days Payable of 204.12 is 30% below median its 10-year median of 291.12. Over the past 10 years, this metric has ranged from a low of 157.31 to a high of 4,393.73. The Biotechnology industry median Days Payable is 113.56. Camurus AB's value of 204.12 is 79.7% above this industry median. Based on the distribution chart, Camurus AB ranks #280 out of 708 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Camurus AB has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #280 out of 708 companies for Days Payable. This puts Camurus AB in the upper half of its industry. The industry median Days Payable is 113.56. Camurus AB's value of 204.12 is 79.7% above this benchmark. Historically, Camurus AB's own Days Payable has ranged from 157.31 to 4,393.73 over the past decade. While the company's 10-year median is 291.12 vs. the industry median of 113.56, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Days Payable of 204.12 is 79.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Days Payable is 204.12, which is 30% below median its own 10-year median of 291.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.22, compared to a current price of $54.00 — trading 35.1% below its estimated fair value. The current Days Payable is 204.12, which is 30% below median its 10-year median of 291.12 and 79.7% above the Biotechnology industry median of 113.56. Camurus AB's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Days Payable is 204.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $54.00 is trading 35.1% below its estimated GF Value™ of $83.22.
GuruFocus considers Camurus AB to be Significantly Undervalued.
Key valuation signals for CAMRF:
Days Payable: 204.12 (30% below median its 10-year median of 291.12)
GF Value™: $83.22 vs. price of $54.00 (35.1% below fair value)
Industry Position: 79.7% above the Biotechnology median (#280 of 708)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
79GF Score
Get the complete analysis for CAMRF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
